nach oben

International Journal of Clinical Oncology

Erschienen in:

03.08.2020 | Original Article

Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer

verfasst von: Masashi Kato, Akihiro Hirakawa, Yumiko Kobayashi, Akiyuki Yamamoto, Yushi Naito, Kosuke Tochigi, Tomoyasu Sano, Shohei Ishida, Yasuhito Funahashi, Takashi Fujita, Yoshihisa Matsukawa, Ryohei Hattori, Toyonori Tsuzuki

Erschienen in: International Journal of Clinical Oncology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The number of core needle biopsies in metastatic prostate cancer cases are sometimes reduced to avoid various complications. We analyzed whether core needle biopsy number influence IDC-P detection rate in patients with metastatic castration-sensitive prostate cancer (mHSPC).

Methods

We retrospectively evaluated data from 150 patients diagnosed with mHSPC. Subjects were allocated to three groups according to the number of core biopsies performed: ≤ 5, 6–9, and ≥ 10. The study endpoints were the cancer-specific survival (CSS) and overall survival (OS) rates.

Results

For patients who underwent ≥ 10 core biopsies, a significant difference on CSS was detected between with or without IDC-P (P = 0.016). On the other hand, the difference decreased as the number of core biopsies became smaller (6–9; P = 0.322 and ≤ 5; P = 0.815). A similar trend was identified for the OS outcome. A significant difference on OS was also found between with or without IDC-P in patients who underwent ≥ 10 and 6–9 core needle biopsies (P = 0.0002 and 0.017, respectively), but not in those who underwent ≤ 5 core biopsies (P = 0.341). IDC-P served as a stronger prognostic marker for CSS and OS than did the other factors included in the multivariate analysis for patients had ≥ 10 core biopsies (P = 0.016, and P = 0.0014, respectively).

Conclusions

Given the IDC-P detection and its value as a prognostic marker, we propose the performance of ≥ 10 core biopsy procedures in patients diagnosed with mHSPC to minimize the sampling error of the IDC-P.

Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746. https://doi.org/10.1056/NEJMoa1503747CrossRefPubMedPubMedCentral

Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352–360. https://doi.org/10.1056/NEJMoa1704174CrossRefPubMed

Davis ID, Martin AJ, Stockler MR et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381(2):121–131. https://doi.org/10.1056/NEJMoa1903835CrossRefPubMed

Chi KN, Agarwal N, Bjartell A et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381(1):13–24. https://doi.org/10.1056/NEJMoa1903307CrossRefPubMed

Epstein JI, Egevad L, Amin MB et al (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 40(2):244–252. https://doi.org/10.1097/pas.0000000000000530CrossRef

Kato M, Tsuzuki T, Kimura K et al (2016) The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation. Mod Pathol 29(2):166–173. https://doi.org/10.1038/modpathol.2015.146CrossRefPubMed

Kimura K, Tsuzuki T, Kato M et al (2014) Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 74(6):680–687. https://doi.org/10.1002/pros.22786CrossRefPubMed

Zhao T, Liao B, Yao J et al (2015) Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer? Prostate 75(3):225–232. https://doi.org/10.1002/pros.22906CrossRefPubMed

Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 71 (4):618-629. https://doi.org/10.1016/j.eururo.2016.08.003

10.

Mohler James L, Antonarakis Emmanuel S, Armstrong AJ (2019) National comprehensive cancer network. NCCN Clin Pract Guide Oncol Prosrtate Cancer. https://doi.org/10.6004/jnccn.2019.0023CrossRef

11.

Kato M, Hirakawa A, Kobayashi YM et al (2019) The influence of the presence of intraductal carcinoma of the prostate on the grade group system’s prognostic performance. Prostate 79(10):1065–1070. https://doi.org/10.1002/pros.23818CrossRefPubMed

12.

Porter LH, Lawrence MG, Ilic D et al (2017) Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories. Eur Urol 72(4):492–495. https://doi.org/10.1016/j.eururo.2017.03.013CrossRefPubMed

13.

Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumors, 8th edn. Wiley-Blackwell, Oxford

14.

Gooley TA, Leisenring W, Crowley J et al (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6):695–706CrossRef

15.

Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef

16.

Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef

17.

Srigley J, Zhou M, Allan R (eds) (2017) Protocol for the examination of specimens from patients with carcinoma of the prostate gland v 4.0. College of American Pathologists,

18.

Bottcher R, Kweldam CF, Livingstone J et al (2018) Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer 18(1):8. https://doi.org/10.1186/s12885-017-3976-zCrossRefPubMedPubMedCentral

19.

Chua MLK, Lo W, Pintilie M et al (2017) A Prostate Cancer “Nimbosus”: genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. Eur Urol 72(5):665–674. https://doi.org/10.1016/j.eururo.2017.04.034CrossRefPubMed

20.

Lindberg J, Kristiansen A, Wiklund P et al (2015) Tracking the origin of metastatic prostate cancer. Eur Urol 67(5):819–822. https://doi.org/10.1016/j.eururo.2014.09.006CrossRefPubMed

21.

Shah RB, Shore KT, Yoon J et al (2019) PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma). Prostate 79(11):1267–1273. https://doi.org/10.1002/pros.23831CrossRefPubMed

22.

Taylor RA, Fraser M, Rebello RJ et al (2019) The influence of BRCA2 mutation on localized prostate cancer. Nat Rev Urol 16(5):281–290. https://doi.org/10.1038/s41585-019-0164-8CrossRefPubMed

23.

de Bono J, Mateo J, Fizazi K et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa1911440CrossRefPubMed

24.

Mateo J, Porta N, Bianchini D et al (2020) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 21(1):162–174. https://doi.org/10.1016/s1470-2045(19)30684-9CrossRefPubMedPubMedCentral

25.

Han B, Suleman K, Wang L et al (2010) ETS gene aberrations in atypical cribriform lesions of the prostate: implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol 34(4):478–485. https://doi.org/10.1097/PAS.0b013e3181d6827bCrossRefPubMed

26.

Taylor AS, Morgan TM, Wallington DG et al (2020) Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier. Prostate 80(2):146–152. https://doi.org/10.1002/pros.23926CrossRefPubMed

27.

Valerio M, Donaldson I, Emberton M et al (2015) Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review. Eur Urol 68(1):8–19. https://doi.org/10.1016/j.eururo.2014.10.026CrossRefPubMed

28.

Drost FH, Osses D, Nieboer D et al (2020) Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a cochrane systematic review and meta-analysis. Eur Urol 77(1):78–94. https://doi.org/10.1016/j.eururo.2019.06.023CrossRefPubMed

29.

Siddiqui MM, Rais-Bahrami S, Turkbey B et al (2015) Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313(4):390–397. https://doi.org/10.1001/jama.2014.17942CrossRefPubMedPubMedCentral

30.

Truong M, Feng C, Hollenberg G et al (2018) A comprehensive analysis of cribriform morphology on magnetic resonance imaging/ultrasound fusion biopsy correlated with radical prostatectomy specimens. J Urol 199(1):106–113. https://doi.org/10.1016/j.juro.2017.07.037CrossRefPubMed

31.

Truong M, Hollenberg G, Weinberg E et al (2017) Impact of gleason subtype on prostate cancer detection using multiparametric magnetic resonance imaging: correlation with final histopathology. J Urol 198(2):316–321. https://doi.org/10.1016/j.juro.2017.01.077CrossRefPubMed

32.

Corcoran NM, Hovens CM, Hong MK et al (2012) Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU Int 109(5):660–664. https://doi.org/10.1111/j.1464-410X.2011.10543.xCrossRefPubMed

33.

Epstein JI, Feng Z, Trock BJ et al (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61(5):1019–1024. https://doi.org/10.1016/j.eururo.2012.01.050CrossRefPubMedPubMedCentral

34.

Prendeville S, Gertner M, Maganti M et al (2018) Role of magnetic resonance imaging targeted biopsy in detection of prostate cancer harboring adverse pathological features of intraductal carcinoma and invasive cribriform carcinoma. J Urol 200(1):104–113. https://doi.org/10.1016/j.juro.2018.01.081CrossRefPubMed

Titel: Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer
verfasst von: Masashi Kato
Akihiro Hirakawa
Yumiko Kobayashi
Akiyuki Yamamoto
Yushi Naito
Kosuke Tochigi
Tomoyasu Sano
Shohei Ishida
Yasuhito Funahashi
Takashi Fujita
Yoshihisa Matsukawa
Ryohei Hattori
Toyonori Tsuzuki
Publikationsdatum: 03.08.2020
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 12/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-020-01756-0

The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study

Original Article

Effect of general self-efficacy on promoting health-related quality of life during recovery from radical prostatectomy: a 1-year prospective study

Original Article

HOXC9 overexpression is associated with gastric cancer progression and a prognostic marker for poor survival in gastric cancer patients

Original Article

Mean platelet volume may not be a significant prognostic factor in patients with metastatic castration-resistant prostate cancer

Letter to the Editor

A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302)

Open Access
Original Article

YAP promotes self-renewal of gastric cancer cells by inhibiting expression of L-PTGDS and PTGDR2

Original Article

Neu im Fachgebiet Onkologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

16.01.2025
Zöliakie
Nachrichten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

15.01.2025
Melanom
Nachrichten

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer